Share on StockTwits

Athersys (NASDAQ:ATHX) CEO Bokkelen Gil Van unloaded 9,500 shares of the company’s stock in a transaction dated Thursday, June 19th. The shares were sold at an average price of $1.63, for a total transaction of $15,485.00. Following the completion of the transaction, the chief executive officer now directly owns 926,995 shares in the company, valued at approximately $1,511,002. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

A number of analysts have recently weighed in on ATHX shares. Analysts at Edison Investment Research reiterated a “neutral” rating on shares of Athersys in a research note on Tuesday, May 6th. Analysts at First Analysis initiated coverage on shares of Athersys in a research note on Tuesday, April 29th. They set an “overweight” rating and a $5.00 price target on the stock.

Shares of Athersys (NASDAQ:ATHX) traded down 2.42% during mid-day trading on Thursday, hitting $1.61. The stock had a trading volume of 910,639 shares. Athersys has a 52-week low of $1.08 and a 52-week high of $4.33. The stock’s 50-day moving average is $1.57 and its 200-day moving average is $2.7. The company’s market cap is $124.0 million.

Athersys (NASDAQ:ATHX) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.09) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.10) by $0.01. The company had revenue of $0.71 million for the quarter, compared to the consensus estimate of $0.66 million. The company’s quarterly revenue was up 116.9% on a year-over-year basis. Analysts expect that Athersys will post $-0.40 EPS for the current fiscal year.

Athersys, Inc is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and improve the quality of human life.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.